1. Home
  2. CSBR vs AARD Comparison

CSBR vs AARD Comparison

Compare CSBR & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Champions Oncology Inc.

CSBR

Champions Oncology Inc.

N/A

Current Price

$6.25

Market Cap

83.5M

Sector

Health Care

ML Signal

N/A

Logo Aardvark Therapeutics Inc.

AARD

Aardvark Therapeutics Inc.

HOLD

Current Price

$4.57

Market Cap

85.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSBR
AARD
Founded
1985
2017
Country
United States
United States
Employees
N/A
40
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.5M
85.7M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
CSBR
AARD
Price
$6.25
$4.57
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$15.29
AVG Volume (30 Days)
5.7K
120.0K
Earning Date
03-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
161.11
N/A
EPS
N/A
N/A
Revenue
$2,900,000.00
N/A
Revenue This Year
$4.84
N/A
Revenue Next Year
$11.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.50
$3.35
52 Week High
$9.63
$17.94

Technical Indicators

Market Signals
Indicator
CSBR
AARD
Relative Strength Index (RSI) 57.68 40.70
Support Level $6.14 $3.35
Resistance Level $6.29 $6.01
Average True Range (ATR) 0.25 0.53
MACD 0.03 0.03
Stochastic Oscillator 79.71 18.22

Price Performance

Historical Comparison
CSBR
AARD

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

About AARD Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Share on Social Networks: